Steven Stellman - Nonsteroidal antiinflammatory drugs and colorectal cancer

Document created by Steven Stellman on Dec 1, 2016
Version 1Show Document
  • View in full screen mode

  Publication Details (including relevant citation   information):

  Muscat, J. E., Stellman, S. D., Wynder, E. L. 74 (7)   1847-54-

  Abstract: BACKGROUND: The association between   the use of nonsteroidal antiinflammatory drugs (NSAID) and large   bowel cancer was examined in a hospital-based case-control study   of 511 patients with colorectal cancer and 500 age-sex matched   control subjects. METHODS: Regular NSAID use was defined as at   least 3 times per week for 1 or more years before the date of   hospital admission. Odds ratios (OR) were calculated by the   duration of NSAID use and according to the medical reasons given   for taking NSAIDs. RESULTS: The prevalences of regular NSAID use   were 15% for male patients, 8% for female patients, and 20% for   control subjects. Overall, NSAID use was associated with a   statistically significant risk reduction in men (OR = 0.64; 95%   confidence interval [CI], 0.42-0.97) and in women (OR = 0.32; 95%   CI, 0.18-0.57). The estimate decreased with duration among men   but increased with duration among women. The risk reduction among   patients who took NSAIDs to prevent heart disease was 0.67 (95%   CI, 0.38-1.13) for men and 0.43 (95% CI, 0.12-1.59) for women.   For treating headache pain, the OR was 0.5 (95% CI, 0.23-1.09)   for men and 0.64 (95% CI, 0.25-1.62) for women. The use of NSAID   was not found to be associated with the stage of cancer at   diagnosis. The OR for daily acetaminophen use was 1.07 (95% CI,   0.35-3.23) for men and 0.59 (95% CI, 0.27-1.25) for women.   CONCLUSIONS: The regular use of NSAIDs was associated with an   overall significant risk reduction of colorectal cancer in men   and in women. Among female patients, the greater protective   effect associated with short term NSAID use compared with long   term NSAID use may reflect a sampling bias.

  Address (URL):